HansaBioMed Report issue

For profit Phase 2 Phase 3
Founded: Tallinn Estonia (2007)
Status: Acquired by Lonza (2017)

Organization Overview

First Clinical Trial
2013
NCT01802697
First Marketed Drug
2017
epinephrine (levophed)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hansa Biopharma AB | Hansa Medical AB | HANSAMED INC

Active Ingredients

Marketed Drugs (2)

articaine (Septocaine) (2017)

epinephrine (levophed) (2017)

Drugs in Phase 3 Trials (4)

cyclophosphamide (cytoxan) (1 trial)

eculizumab (Soliris) (1 trial)

imlifidase (15 trials)

immune globulin (human) (Gamastan) (1 trial)

Drugs in Phase 2 Trials (1)

blood plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anti-Glomerular Basement Membrane Disease (Phase 2)

Guillain-Barre Syndrome (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombotic Thrombocytopenic (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 5